李玉华

南方医科大学珠江医院血液内科科室主任/主任医师

教授/博士生导师

Email:liyuhua2011gz@163.com

个人简介

 南方医科大学珠江医院血液内科科室主任，教授，主任医师，博士生导师。为教育部新世纪优秀人才、广东省杰出青年医学人才、羊城好医生、校级教学名师。担任中国研究型医院学会血液病精准诊疗专业委员会副主任委员、中国研究型医院学会生物治疗学专业委员会常委、中国医师协会血液科医师分会委员、中国医院协会罕见病专业委员会委员、中国抗癌协会血液肿瘤专业委员会中国骨髓增生异常综合征和骨髓增殖性肿瘤工作组专家委员会委员、广东省抗癌协会血液肿瘤专业委员会常委、广东省基层医药学会血液病学专业委员会主任委员、广东省女医师协会第五届理事会副会长、广东省女医师协会血液病学专业委员会主任委员、广东省医师协会血液科医师分会副主任委员、广东省医疗安全协会血液病学分会副主任委员以及《血栓与止血学》第八届编审委员会常委、Frontiers in Pharmacology审稿编委、Experimental Hematology & Oncology审稿专家、《中国肿瘤生物治疗杂志》审稿专家等。

 长期致力于血液恶性肿瘤的临床和基础研究，并积极推动研究成果的临床转化，研究方向包括：恶性肿瘤的免疫生物治疗——新型CAR-T细胞和个体化新抗原疫苗研发；CAR-T细胞个体化新抗原疫苗治疗难治/复发血液系统恶性肿瘤的临床效应及机制研究。先后获得军队科技进步二等奖1项，广东省科技进步奖（二等奖、三等奖各1项），美国Arizona State University博士后科研奖1项，中国女医师协会五洲女子科技奖1项。

 近年来研究成果以第一/通讯作者在Nat Nanotechnol.、Nat Biomed Eng.、Proc Natl Acad Sci.等国际高影响力期刊上发表SCI论文130余篇，单篇最高影响因子40.523；申请国内外发明专利14项，已授权国家发明专利10项、美国发明专利1项；相继承担国家自然科学基金一联合重点支持项目 (合作单位负责人)、国家自然科学基金委面上项目、国家自然科学基金委青年项目、广东省自然科学基金重点项目、广州市健康医疗协同创新重大专项等课题20余项；主编及副主编专著3部；参编专家共识或指南7部。

研究领域

   临床上：单倍体（遗传半相合）造血干细胞移植、CAR-T 细胞治疗、造血淋巴系统疾病个体化精准诊疗等代表性特色诊疗技术。在科研上：建成肿瘤生物治疗（肿瘤疫苗治疗、CAR-T细胞治疗、肿瘤疫苗联合CAR-T细胞治疗）、难治性白血病耐药机制研究（TKIS耐药机制研究、白血病靶向药物研发）、干细胞基因治疗和功能性研究（iPSCs 技术研发、难治白血病治疗）3大研究平台。

   于国内率先开展CAR-T细胞的临床研究，并长期从事肿瘤生物治疗的研究，相关研究成果发表于Nature子刊Nature Nanotechnology（IF=39.213）Nature Biomedical Engineering（IF=18.925）、Proc Natl Acad Sci USA（IF=9.412）、Haematologica（IF=7.116）等著名期刊。

个人成果

[1]. Changlong Wang#, Wei Zhang#, Yanjie He#, Zirui Gao, Liyuan Liu, Siyao Yu, Yuxing Hu, Shuang Wang, Chaochao Zhao, Hui Li, Jinan Shi, Wu Zhou, Feng Li, Hua Yue, Yuhua Li*, Wei Wei*, Guanghui Ma* and Ding Ma*. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nature Nanotechnology. 2021 Oct 25. 16(12):1413-1423.（IF=39.213）

[2]. Xiaoling Xie#, Yuxing Hu#, Tong Ye#, Yiran Chen, Lijuan Zhou, Feng Li, Xiaobo Xi, Shuang Wang, Yanjie He, Xiaoyong Gao, Wei Wei*, Guanghui Ma*, Yuhua Li*.Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng. 2020 Oct 12. ;5(5):414-428. (IF=25.613)

[3]. Xiao XY#, Huang SK#, Chen SF，Wang YZ，Sun QH，Xu XJ*，Li YH*. Mechanisms of cytokine release syndrome and neurotoxicity of CART-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367. (IF=11.161）

[4]. Li M#, Yang J#, Zhang L#, Tu S, Zhou X, Tan Z, Zhou W*, He Y*, Li Y*. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res.2019 May 22. (IF=11.161）

[5]. Chen Y#, Xie X#, Wu A, Wang L, Hu Y, Zhang H, Li Y*. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res. 2018. 37(1):12. (IF=11.161）

[6]. Huang R#, Hayashi Y#, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang K, Jordan MB, Li Y*, Huang G*. HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. Haematologica. 2017 Nov. 102(11):1956-1968. (IF=9.941)

[6]. Li D, Wang L, Hou J, Shen Q, Chen Q, Wang X, Du J, Cai X, Shan Y, Zhang T, Zhou T, Shi X, Li Y*, Zhang H*, Pan G*.Optimized-Approaches for Generation of Integration-free iPSCs from Human Urine-Derived Cells with Small Molecules and Autologous Feeder. Stem Cell Reports. 2016. 6(5):717-728. (最新IF=7.765，发表时IF=7.338，1区)

[7]. Guo Z, Tu S, Yu S, Wu L, Pan W, Chang N, Zhou X, Song C, Li Y, He Y. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci. 2021 Apr;112(4):1357-1368. (最新IF=6.716，发表时IF=4.966，1区)

[8]. Xinjie Xu#, Shengkang Huang#, Xinyi Xiao#, Qihang Sun, Xiaoqian Liang, Sifei Chen, Zijing Zhao, Zhaochang Huo, Sanfang Tu*, Yuhua Li*. Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Front Immunol. 2021 Feb 10;11:569117. (最新IF=7.561，发表时IF=5.085，1区)

[9]. Xiaoling Xie#, Yuxing Hu#, Tong Ye#, Yiran Chen, Lijuan Zhou, Feng Li, Xiaobo Xi, Shuang Wang, Yanjie He, Xiaoyong Gao, Wei Wei*, Guanghui Ma*, Yuhua Li*. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng. 2020 Oct 12. （IF=18.925）

[10]. Yiran Chen, Xiaoling Xie, Chunsheng Wang, Yuxing Hu, Honghao Zhang, Lenghe Zhang, Sanfang Tu, Yanjie He*, Yuhua Li*. Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities. Cell Death Dis. 2020 Sep 1;11(8):712.（IF=6.304）

[11]. Xuan Zhou#, Sanfang Tu#, Chunsheng Wang#, Rui Huang, Lan Deng, Chaoyang Song, Chunyan Yue, Yanjie He, Jilong Yang, Zhao Liang, Anqin Wu, Meifang Li, Weijun Zhou, Jingwen Du, Zhenling Guo, Yongqian Li, Cheng Jiao, Yuchen Liu, Lung-Ji Chang*, Yuhua Li*. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B cell Non-Hodgkin Lymphomas. Front Immunol. 2020 Nov 27;11:564099.（IF=5.085）

[12]. Binyan Xu#, Rong Hu#, Zhao Liang, Tong Chen, Jianyu Chen, Yuxing Hu, Yirong Jiang*, Yuhua Li*. Metabolic regulation of the bone marrow microenvironment in leukemia. Blood Rev. 100786. doi:10.1016/j.blre.2020.100786 (2020).（IF=5.823）

[13]. Yuting Wang#, Lenghe Zhang#, Xia Tang, Jinfeng Luo, Zhengchao Tu, Kaili Jiang, Xiaomei Ren, Fang Xu, Shingpan Chan, Yuhua Li*, Zhang Zhang*, Ke Ding*. GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo. Transl Oncol. 2020 Apr;13(4):100766.（IF=3.558）

[14]. Nie Y#, Lu W#, Chen D#, Tu H, Guo Z, Zhou X, Li M, Tu S*, Li Y*. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020 May 27;8:18.（IF=4.866）

[15].  Xie X#, Chen Y#, Hu Y#, He Y, Zhang H, Li Y*. Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma. Mol Cancer Ther. 2019 Dec;18(12):2258-2269.（IF=5.615）

[16]. Tu SF#, Zhou X#, Guo ZL, Huang R, Yue CY, He YJ, Li MF, Chen YR, Liu YC, Chang LJ, Li YH*. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma. Front Oncol. 2019 Dec 4; 9:1350.（IF=4.848）

[17]. Xu X#, Sun Q#, Liang X#, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S*, Li Y*. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol. 2019 Nov 12; 10:2664.（IF=5.085）

[18]. Tu S#, Huang R#, Guo Z, Deng L, Song C, Zhou X, Yue C, Zhang L, He Y, Yang J, Liang Z, Du J, Cao P, Li Y, Chang LJ*, Li YH*. Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome. Am J Hematol. 2019 Dec;94(12): E322-E325.（IF=6.973）

[19]. Zhang H#, Zhou L#, Zhou W#, Xie X, Wu M, Chen Y, Hu Y, Du J, He Y, Li Y*. EPS8-mediated regulation of multiple myeloma cell growth and survival. Am J Cancer Res. 2019 Aug 1;9(8):1622-1634.（IF=5.177）

[20]. Li M#, Yang J#, Zhang L#, Tu S, Zhou X, Tan Z, Zhou W*, He Y*, Li Y*. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res. 2019 May 22;38(1):211.（IF=7.068）

[21]. Wu MR#, Zhang LT#, Zhang HZ, Ning JX, Tu SF, He YJ, Li YH*. CD19 Chimeric Antigen Receptor–Redirected T Cells Combined with Eps8 Peptide Derived Dendritic Cell Vaccine in Leukemia. Cytotherapy. 2019 Jun;21(6):659-670.（IF=4.218）

[22]. Xie X#, Zhou W#, Hu Y, Chen Y, Zhang H, Li Y*. A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. Cell Death Dis. 2018 Mar 7;9(3):379.（IF=6.304）

[23]. Chen Y#, Xie X#, Wu A, Wang L, Hu Y, Zhang H, Li Y*. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res 2018, 37:12.（IF=7.068）

[24]. Huang R#, Hayashi Y#, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang K, Jordan MB, Li Y*, Huang G*. HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. Haematologica. 2017 Nov;102(11):1956-1968.（IF=7.116）

[25]. Li Y#*, Zhou W#, Du J, Jiang C, Xie X, Xue T, He Y*. Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen. Cancer Immunol Immunother 2015; 64(2): 259-269. （IF=5.442）

[26]. Li Y#, Wang S, Scarpellini G, Gunn B, Xin W, Wanda SY, Roland KL, Curtiss RR. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci U S A 2009; 106(2):593-598. （IF=9.412）